简介
吴德燕?博士，副研究员。2014年6月博士（硕博连读）毕业于华东理工大学药学院，同年进入上海睿智化学研究有限公司从事药学研究工作一年、期间学习了企业在助力新药研发中的研究策略。于2015年7月加入中山大学药学院、罗海彬教授科研团队工作至今。研究方向包括：药物分子设计、结构优化及作用机制研究；活性天然产物全合成、结构修饰及构效关系研究；药用优势骨架的有机不对称合成研究。近年来与罗海彬教授合作，参与构建基于靶标“磷酸二酯酶（PDEs）”的药物筛选体系，目前研究方向聚焦于“基于靶标PDEs的全新药物设计、结构改造及成药性优化”。已在国内外重要学术刊物，包括J. Med. Chem., Org. Lett., Chem. Commun., PNAS, ACS Chem. Neurosci., Front. Chem., Biochem. Pharmacol., J. Chem. Inf. Model., Bioorg. Med. Chem., Bioorg. Med. Chem. Lett., Chem.-Eur. J., J. Enzyme Inhib. Med. Chem.和Med. Chem. Res.等发表论文29篇，通讯或第一作者论文15篇；发明专利10项，其中2项已获得授权；主持国家自然科学基金面上项目、国家自然科学基金青年基金、广州市科技创新发展专项-民生科技攻关计划、广东省自然科学基金等项目6项，总经费298万余元。目前已有多个项目分别针对肺动脉高压、肺纤维化、男性勃起功能障碍、肿瘤多药耐药（MDR）等疾病的研究取得重大进展，其中主持一项针对肺动脉高压治疗的1.1类创新化学药已进入临床前研究、预计2021年底提交临床试验申请。
学术/社会任职
Bioorg.?Chem.、Arab. J. Sci. Eng.等高水平期刊审稿人。
科研项目
国家自然科学基金面上项目，**，吡咯色原酮类PDE5特异性抑制剂的设计、抗肺动脉高压活性及作用机制研究，2019.01-2022.12，55万（直接经费），在研
广州市科技创新发展专项—民生科技攻关计划项目，5，抗肺动脉高压I类创新化学药（PDE5抑制剂罗达那非）的临床前研究，2018.04-2021.03，200万，在研
国家自然科学基金青年基金项目，**，抗慢性阻塞性肺病PDE4高选择性抑制剂的发现:天然产物桑辛素M的结构优化及生物活性研究，2017.01-2019.12，17.3万（直接经费），已结题
广东省自然科学基金博士启动项目，2016A，老药新用导向的抗菌活性化合物发现及结构优化，2016.06-2019.06，10万，已结题
广东省医学科研基金项目，A**，天然产物Moracin M导向的PDE4抑制剂的设计、合成及活性研究，2016.07-2018.06，1万元，已结题
中山大学青年教师培育基金项目，17ykpy20，抗肺动脉高压PDE5高选择性抑制剂的设计、合成及生物活性研究，2017.01-2019.12，15万元，已结题
代表性论文
Huang, Y.-Y.^#; Yu, Y.-F.^#; Zhang, C.^#; Chen, Y.; Zhou, Q.; Li, Z.; Zhou, S.; Li, Z.; Guo, L.; Wu, D.^*; Wu, Y.^*; Luo, H.-B.^*?Validation of Phosphodiesterase-10?as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.?J. Med. Chem.?2019,?62, 3707-372
Wu, D.^#; Huang, Y.^#; Chen, Y.^#; Huang, Y.-Y.; Geng, H.; Zhang, T.; Zhang, C.; Li, Z.; Guo, L.; Chen, J.; Luo, H.-B.^*?Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure–Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension. J. Med. Chem. 2018,?61, 8468-8473. 封面论文
Wu, D.^#; Zhang, T.^#; Chen, Y.; Huang, Y.; Geng, H.; Yu, Y.; Zhang, C.; Lai, Z.; Wu, Y.; Guo, X.; Chen, J.^*; Luo, H.-B.^*?Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.. J. Med. Chem. 2017,?60, 6622-6637.?封面论文
Yu, Y.-F.^#; Zhang, C.^#; Huang, Y.-Y.^#; Zhang, S.; Zhou, Q.; Li, X.; Lai, Z.; Li, Z.; Gao, Y.; Wu, Y.; Guo, L.^*; Wu, D.^*; Luo, H.-B., Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors. ACS Chem.?Neurosci. 2020, 11, 1058-1071.
Li, J.^#; Chen, J.-Y.^#; Deng, Y.-L.; Zhou, Q.; Wu, Y.^*; Wu, D.^*.; Luo, H.-B., Structure-Based Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel PDE10 Inhibitors?With Antioxidant Activities. Front. Chem.?2018,?6, 167.
Wu, Y.; Li, Z.; Huang, Y.-Y.; Wu, D.; Luo, H.-B.^*?Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer’s Disease. J. Med. Chem. 2018,?61, 5467-5483.
Li, Z.^?#; Li, X.^?#; Huang, Y.-Y.^?#; Wu, Y.; Liu, R.; Zhou, L.; Lin, Y.; Wu, D.; Zhang, L.;?Liu, H.; Xu, X.; Yu, K.; Zhang, Y.; Cui, J.; Zhan, C.-G.^?*; Wang,?X.^?*; Luo, H.-B.^?*?Identify potent SARS-CoV-2 main protease inhibitors?via accelerated free energy perturbation-based virtual screening of existing drugs.?PNAS 2020,?117, 27381-27387.
Feng, S.^?#;?Zhou, H.^?#; Wu, D.;?Zheng, D.; Qu, B.; Liu, R.; Zhang, C.; Li, Z.;?Xie,?Y.^?*;?Luo, H.-B.^?*?Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: total synthesis and discovery of potent MDR reversal agents, Acta Pharm.?Sin. B 2020, 10, 327-343.
Huang, Y.^#; Liu, X.^#; Wu, D.; Tang, G.; Lai, Z.; Zheng, X.^*; Yin, S.^*; Luo, H.-B.^*?The Discovery, Complex Crystal Structure, and Recognition Mechanism of a Novel Natural PDE4 inhibitor from Selaginella Pulvinata. Biochem.?Pharmacol.?2017,?130, 51-5
Zhang, C.; Feng, L.-J.; Huang, Y.; Wu, D.; Li, Z.; Zhou, Q.; Wu, Y.; Luo, H.-B., Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay. J. Chem. Inform. Model.?2017,?57, 355-364.
Li, Z.^#; Huang, Y.^#; Wu, Y.; Chen, J.; Wu, D.; Zhan, C.-G.^*; Luo, H.-B.^*?Absolute Binding Free Energy Calculation and Design of a Subnanomolar Inhibitor of Phosphodiesterase-10. J. Med. Chem. 2019,?62, 2099-21
Liang, J.^#; Huang, Y.-Y.^#; Zhou, Q.^#; Gao, Y.; Li, Z.; Wu, D.; Yu, S.; Guo, L.; Chen, Z.; Huang, L.; Liang, S. H.; He, X.^*; Wu, R.^*; Luo, H.-B.^*?Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia. J. Med. Chem. 2020,?63, 3370-3380.
Wu, D.; Zhang, X.; Xu, Y.; Xue, Y.; Li, J.; Wang, W.^*; Zhu, J.^*?Organocatalytic Enantioselective Friedel–Crafts Reaction?of 1-Naphthols with Isatins and an Unexpected Spontaneous Dehydration Process. Asian J.?Org.?Chem. 2014,?3, 480-486.
Liu, L.; Wu, D.; Zheng, S.; Li, T.; Li, X.; Wang, S.; Li, J.; Li, H.^*; Wang, W.^*?Synthesis of Highly Functionalized Chiral 3,3′-Disubstituted Oxindoles via an Organocatalytic Enantioselective Michael Addition?of Nitroalkanes to Indolylidenecyanoacetates. Organic Lett. 2012,?14, 134-137.
Liu, L.; Wu, D.; Li, X.; Wang, S.; Li, H.; Li, J.^*; Wang, W.^*?Organocatalytic Enantioselective Conjugate Addition?of Ketones to Isatylidine Malononitriles. Chem.Commun. 2012,?48, 1692-1694.
?